N. S. Pokrovskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
N. S. Pokrovskiy has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- E. T. Abdullin
Lomonosov Moscow State University
7 shared publications - Anastasia Doronenkova
S.S. Yudin City Clinical Hospital, Moscow, Russia
5 shared publications - I. A. Zaigrayev
Sergey Yudin City Clinical Hospital, Moscow, Russia;National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
5 shared publications - Nikolay Krotenko
S.S. Yudin City Clinical Hospital, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia
5 shared publications - Marina Grinenko
S.S. Yudin City Clinical Hospital, Moscow, Russia
4 shared publications - Olga Viktorovna Ignatenko
Sergey Yudin City Clinical Hospital, Moscow, Russia;Russian Medical Academy of Continuous Professional Education, Moscow, Russia;Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Science Publishing Group in International Journal of Clinical and Experimental Medical Sciences
- Vol. 12 (5) , 82-95
Prognostic Role of Nucleosomes Containing Histones of the H3.1 Type in Septic Shock: Results of a Prospective Study
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.
- 23 October 2026
- Published by Science Publishing Group in International Journal of Clinical and Experimental Medical Sciences
- Vol. 12 (5) , 82-95
Open AccessPrognostic Role of Nucleosomes Containing Histones of the H3.1 Type in Septic Shock: Results of a Prospective Study
Cell-free DNA (cfDNA) and neutrophil extracellular traps (NETs), specifically marked by histone type 3.1, play a dual pathogenic role in sepsis by reflecting cellular damage and directly exacerbating tissue injury, highlighting their clinical relevance for extracorporeal elimination therapies. To evaluate their prognostic value, we conducted a prospective, single-center observational study quantifying nucleosomes containing histones of the H3.1 type (Nu.H3.1) in 52 adult patients with septic shock admitted to an intensive care unit between August 2023 and May 2024. The cohort (64% male) had a mean SOFA score of 10±4 and an APACHE II score of 22±7. The H3.1-nuc concentration was 4658 ± 3962 ng/mL, and the median cfDNA level was 3041 (876–7815) ng/mL. Statistical analysis revealed that Nu.H3.1 levels significantly and positively correlated with cfDNA (r=0.67; p=0.0001), serum lactate (r=0.4; p=0.004), and SOFA scores (r=0.41; p=0.002). Furthermore, Nu.H3.1 demonstrated significant predictive performance for both 28-day mortality (AUC=0.68; 95% CI: 0.53–0.84; p=0.037) and the development of acute kidney injury (AKI) (AUC=0.74; 95% CI: 0.57–0.90; p=0.014). In conclusion, Nu.H3.1 serves as an independent predictor of adverse outcomes in septic shock, with established threshold values identifying patients at high risk for mortality and AKI. These findings suggest that Nu.H3.1 is a promising biomarker for clinical risk stratification and for substantiating indications for the extracorporeal elimination of toxic DNA-associated structures from the systemic circulation.
- Open Access
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3) , 67-71
History and current trends in extracorporeal methods of therapy in rheumatology. Part 1. Treatment of systemic lupus erythematosus
История и современные тенденции экстракорпоральных методов терапии в ревматологии. Часть 1. Лечение системной красной волчанки
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3) , 67-71
Open AccessHistory and current trends in extracorporeal methods of therapy in rheumatology. Part 1. Treatment of systemic lupus erythematosus
История и современные тенденции экстракорпоральных методов терапии в ревматологии. Часть 1. Лечение системной красной волчанки
- Open Access
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 58-72
Prognostic value of histone H3.1-containing nucleosomes in septic shock: a prospective observational study
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.
- 31 January 2026
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 1,p. 58-72
Open AccessPrognostic value of histone H3.1-containing nucleosomes in septic shock: a prospective observational study
INTRODUCTION: Cell free DNA (cfDNA) is of considerable interest as a marker and pathogenesis factor in sepsis. Two processes are sources of cfDNA: cell death with the ingress of the contents of the cell nucleus into the bloodstream and the release of extracellular neutrophil traps (NETs). The marker of NETs formation is histone type 3.1. CfDNA and NETs in sepsis act in a dual role — they characterize the degree of cellular damage and the intensity of the inflammatory response, and at the same time they are etiological agents of these two processes. OBJECTIVE: This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing significant clinical events. MATERIALS AND METHODS: The prospective single-center observational study included 52 patients with septic shock (Sepsis-3 criteria), admitted to the intensive care unit. RESULTS: The total number of patients was n = 52, with the severity score SOFA 10 ± 4. The median concentration of Nu.H3.1 was 4658 ± 3962 ng/ml, cfDNA — 3041 (876–7815) ng/ml. The most significant correlations of Nu.H3.1 were recorded with the lactate level (rxy = 0.4; p = 0.004) and the SOFA scale (rxy = 0.41; p = 0.002). For Nu.H3.1, a significant association with 28-day mortality and AKI was determined. CONCLUSIONS: The study showed that the marker of NETs formation — the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream. Objective. This study aimed to analyze the level of nucleosomes containing histones of the H3.1 type (nucleosomes H3.1) in patients with septic shock, and the correlation of the nucleosome level with clinical and laboratory data of patients, especially the risk of developing acute kidney injury (AKI) and 28-day mortality. Material and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria), admitted to the intensive care unit of the State Healthcare Institution "City Clinical Hospital named after S.S. Yudin" between August 2023 and May 2024. Results. The total number of patients included in the study was n=52 (64% men, 36% women) aged 52.1 ± 17.3 years, with the severity scores SOFA 10±4 and Apache II - 22±7 points, respectively. The median concentration of Nu.H3.1 was 4658± 3962 ng/ml, cfDNA - 3041 (876-7815.0) ng/ml. The correlation between cfDNA and Nu.H3.1 had a noticeable direct relationship (r xy = 0.67, p = 0.0001). The most significant correlations of Nu.H3.1 were recorded with the lactate level (r xy = 0.4, p = 0.004) and the SOFA scale (r xy = 0.41, p = 0.002). For Nu.H3.1, a significant association with 28-day mortality (AUC 0.68, 95% CI (0.53-0.84) p = 0.037) and AKI (AUC 0.74, 95% CI (0.57-0.90) p = 0.014) was determined. The OR for the development of AKI at a concentration of Nu.H3.1> 2731 ng / ml was 6.0 (95% CI: 1.6-26.0, p < 0.018), sensitivity, specificity - 67% and 75%, respectively. For 28-day mortality at a concentration of Nu.H3.1 > 2731 ng / ml, the OR was 4.4 (95% CI: 1.2-15.6; p = 0.03), sensitivity, specificity - 67 and 79%, respectively. Conclusion. The study showed that the marker of NETs formation – the level of Nu.H3.1 is an independent predictor of mortality and the development of AKI in septic shock, its threshold concentration was identified. It was associated with a risks of these significant clinical events. So this level can be considered as a laboratory benchmark in determining the indications for extracorporeal elimination of DNA-containing structures from the bloodstream.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- 30 January 2026
- Published by The Scientific and Practical Society of Emergency Medicine Physicians in Russian Sklifosovsky Journal "Emergency Medical Care"
- Vol. 14 (4)
The Role of Extracellular DNA Among Predictors of Hospital Mortality in Patients with Septic Shock
Introduction. Extracellular DNA (exDNA) is a well-known but poorly understood mediator of sepsis. The aim was to investigate the role of exDNA as an independent predictor of mortality and as a marker of unfavorable clinical phenotype for patients with septic shock. Material and methods. The patients over the age of 18 with septic shock (Sepsis-3 criteria) who were admitted to the intensive care unit of the S.S. Yudin City Clinical Hospital between August 2023 and May 2024 were included in a prospective observational study. Results. Total of fifty-two patients (64% men, 36% women) aged 52.1 ± 17.3 years, with severity of the condition on the SOFA score 10±4 and APACHE II score — 22±7 were included. The exDNA concentration was 3041 (876–7815.0) ng/ml. For exDNA, a significant (p=0,031) association with 28-day mortality was determined (AUC 0.69, 95% CI (0.54–0.84)), and a cut-off point >1893 ng/ml was identified, at which the OR of the hospital death corresponded to 4.3 (95% CI 1.3–15.1, p=0.03). The dependence of the risk of death on the concentration of exDNA (1893 ng/ml), estimated using the Mantel-Cox log-rank test, was statistically significant (p=0.028). The median survival time in the exDNA group >1893 ng/ml was 7 days, and for exDNA levels 1893 ng/ml in patients with septic shock were the level of mixed venous blood lactate (OR 2.0; 95% CI [1.02, 3.92], p=0.044) and SOFA score (OR 1.23; 95% CI [1.02, 1.47], p=0.029). Conclusion. The exDNA level is an independent predictor of mortality in septic shock. Its cut-off point of 1893 ng/ml could be considered as an indication for extracorporeal elimination of exDNA. Point of care laboratory markers of a significant increase in the blood concentration of exDNA were also identified and could be considered as a guide to an intensive care.
- Open Access
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 98-105
Selective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 98-105
Open AccessSelective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
- Open Access
- 11 August 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (4) , 31-42
A new technique for determining cell-free DNA levels and its diagnostic capabilities in patients with septic shock
Introduction. Multiple studies were shown significant role of cell-free DNA (cfDNA) as a marker and mediator of the septic process. Excessive formation of cfDNA is associated with adverse clinical events, which allows to consider this structure as a potential target for therapy.The objective was to study the level of cell-free DNA in patients with septic shock, to evaluate the correlation of the cfDNA level with clinical and laboratory data of patients, and the incidence of acute kidney injury and mortality.Materials and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria) admitted to the intensive care unit of the Moscow City Clinical Hospital named after S. S. Yudin of the Health Department of Moscow from August 2023 to May 2024.Results. The final number of patients included in the study was n = 52 (64% of men and 36% of women) aged 52.1 ± 17.3 years, with a severity score according to SOFA 10 ± 4 and Apache II 22 ± 7 points, respectively. The concentration of cfDNA was 3041 (876–7815.0) ng/ml. Correlation analysis revealed associations of various directions with clinical and laboratory data, the most significant was a moderately positive correlation with the level of lactate (rxy = 0.49, p < 0.0001) and creatinine (rxy = 0.42, p < 0.002). ROC curve analysis showed an association between the level of cfDNA and 28-day mortality (area under the curve 0.69, AUC 95% confidence interval (CI) (0.54–0.84), p = 0.031; cut off level – 1893 ng/ml; sensitivity – 72.2% and specificity – 62.5%). Conclusion. The study found that cfDNA had diagnostic value in septic shock, and the level of cfDNA correlated with clinical diagnostic data and significant clinical events in patients with septic shock.
- 11 August 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 22 (4) , 31-42
Open AccessA new technique for determining cell-free DNA levels and its diagnostic capabilities in patients with septic shock
Introduction. Multiple studies were shown significant role of cell-free DNA (cfDNA) as a marker and mediator of the septic process. Excessive formation of cfDNA is associated with adverse clinical events, which allows to consider this structure as a potential target for therapy.The objective was to study the level of cell-free DNA in patients with septic shock, to evaluate the correlation of the cfDNA level with clinical and laboratory data of patients, and the incidence of acute kidney injury and mortality.Materials and methods. The prospective single-center observational pilot study included 52 patients over 18 years old with septic shock (Sepsis-3 criteria) admitted to the intensive care unit of the Moscow City Clinical Hospital named after S. S. Yudin of the Health Department of Moscow from August 2023 to May 2024.Results. The final number of patients included in the study was n = 52 (64% of men and 36% of women) aged 52.1 ± 17.3 years, with a severity score according to SOFA 10 ± 4 and Apache II 22 ± 7 points, respectively. The concentration of cfDNA was 3041 (876–7815.0) ng/ml. Correlation analysis revealed associations of various directions with clinical and laboratory data, the most significant was a moderately positive correlation with the level of lactate (rxy = 0.49, p < 0.0001) and creatinine (rxy = 0.42, p < 0.002). ROC curve analysis showed an association between the level of cfDNA and 28-day mortality (area under the curve 0.69, AUC 95% confidence interval (CI) (0.54–0.84), p = 0.031; cut off level – 1893 ng/ml; sensitivity – 72.2% and specificity – 62.5%). Conclusion. The study found that cfDNA had diagnostic value in septic shock, and the level of cfDNA correlated with clinical diagnostic data and significant clinical events in patients with septic shock.
- 8 August 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 4
Experience with selective plasmosorption of cfDNA/NETs in a patient with severe acute pancreatitis (case report)
Background. Modality, timing and duration of extracorporeal detoxification (ECD) in patients with severe acute pancreatitis are a controversial and unsolved problem. Objective. To evaluate safety, clinical and laboratory effectiveness of selective plasmosorption (SP) in a patient with severe acute pancreatitis. Material and methods. A 34-year-old patient presented with severe acute pancreatitis complicated by enzymatic shock. Clinical, laboratory and instrumental diagnostic methods were performed. Cell-free deoxyribonucleic acid (cfDNA) SP was used together with standard intensive therapy. The main laboratory parameters were compared. Results. SP significantly reduced the markers of systemic endogenous intoxication: CRP from 64.3 to 29.5 mg/l (54.12%) by the 4th day; leukocytes from 16.2 to 7.8∙109/l (51.85%); IL-1 from 224.1 to 16.7 pg/ml (92.55%); IL-6 from 423.4 to 84.4 pg/ml (80.1%); TNF-α from 627.2 to 102.6 pg/ml (83.64%); cfDNA from 2270 to 10 ng/ml (99.56%), band neutrophils from 18% to 11% (33.89%) by the 7th day. Acid-base state normalized by the 3rd day (pH from 7.15 to 7.31, BE from –11.2 to –2.6, lactate from 4.9 to 1.4 mmol/l). SOFA scores decreased from 6 to 1 point by the 7th day. Conclusion. SP of cfDNA quickly normalizes the main clinical and laboratory parameters, as well as markers of systemic endogenous intoxication.
- 8 August 2025
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 4
Experience with selective plasmosorption of cfDNA/NETs in a patient with severe acute pancreatitis (case report)
Background. Modality, timing and duration of extracorporeal detoxification (ECD) in patients with severe acute pancreatitis are a controversial and unsolved problem. Objective. To evaluate safety, clinical and laboratory effectiveness of selective plasmosorption (SP) in a patient with severe acute pancreatitis. Material and methods. A 34-year-old patient presented with severe acute pancreatitis complicated by enzymatic shock. Clinical, laboratory and instrumental diagnostic methods were performed. Cell-free deoxyribonucleic acid (cfDNA) SP was used together with standard intensive therapy. The main laboratory parameters were compared. Results. SP significantly reduced the markers of systemic endogenous intoxication: CRP from 64.3 to 29.5 mg/l (54.12%) by the 4th day; leukocytes from 16.2 to 7.8∙109/l (51.85%); IL-1 from 224.1 to 16.7 pg/ml (92.55%); IL-6 from 423.4 to 84.4 pg/ml (80.1%); TNF-α from 627.2 to 102.6 pg/ml (83.64%); cfDNA from 2270 to 10 ng/ml (99.56%), band neutrophils from 18% to 11% (33.89%) by the 7th day. Acid-base state normalized by the 3rd day (pH from 7.15 to 7.31, BE from –11.2 to –2.6, lactate from 4.9 to 1.4 mmol/l). SOFA scores decreased from 6 to 1 point by the 7th day. Conclusion. SP of cfDNA quickly normalizes the main clinical and laboratory parameters, as well as markers of systemic endogenous intoxication.
- Open Access
- 30 April 2025
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 2,p. 58-73
Selective plasmofiltration in the treatment of patients with abdominal septic shock: a prospective interventional controlled study
INTRODUCTION: The choice of tactics for the use of extracorporeal detoxification in the form of indications and modality of procedures in patients with abdominal septic shock (SS) remains an unsolved problem. OBJECTIVES: To evaluate the effect of selective plasmofiltration (SPF) as part of complex intensive therapy on the dynamics of markers of systemic inflammatory response syndrome, the severity of the condition and disease outcomes in patients with abdominal SS. MATERIALS AND METHODS: The study included 85 patients with the clinical picture of abdominal SS complicated by acute kidney injury. Group 1 (23 patients) received combined detoxification: SPF and continuous renal replacement therapy (CVVHDF). Group 2 (62 patients) received isolated CVVHDF. A comparative analysis of the main clinical and laboratory parameters and treatment outcomes was performed between the groups. RESULTS: The use of combined detoxification made it possible to reduce markers of systemic endogenous intoxication: C-reactive protein from 225.4 (211; 248.4) to 210.5 (180.39; 230.18) mg/l by the 3rd day of therapy (6.6 %; p = 0.0016), by the 5th–7th–10th days 156.17 (110.67; 180.62), 87 (74.5; 94.1), 62.2 (45.7; 71), respectively (30.7–61.4–72.4 %; p = 0.044; p = 0.0001; p = 0.0001); interleukin-6 demonstrated a decrease of 12.2 % by the 2nd day (p = 0.017) and 35.5, 39.4, 45.7 and 52.4 % by the 3rd–5th–7th–10th days of therapy, respectively (p = 0.022; p = 0.009; p = 0.0018; p = 0.0001); leukocytes from 19.7 (17.7; 22.4) to 17.25 × 109/l (14.65; 19.15) by the 3rd day (12.4 %; p = 0.00045), and 10.9 (9.3; 14.1) by the 10th day (44.7 %; p = 0.00048). Severity of organ dysfunction (SOFA) from 6 (4; 6) on the 1st day to 4 (3; 5) points by the 3rd day of therapy (p = 0.026). A significant difference in survival was obtained (p = 0.037). CONCLUSIONS: Combined detoxification consisting of SPF and CVVHDF allows for rapid normalization of laboratory markers of systemic inflammatory response syndrome and improves patient survival.
- 30 April 2025
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 2,p. 58-73
Open AccessSelective plasmofiltration in the treatment of patients with abdominal septic shock: a prospective interventional controlled study
INTRODUCTION: The choice of tactics for the use of extracorporeal detoxification in the form of indications and modality of procedures in patients with abdominal septic shock (SS) remains an unsolved problem. OBJECTIVES: To evaluate the effect of selective plasmofiltration (SPF) as part of complex intensive therapy on the dynamics of markers of systemic inflammatory response syndrome, the severity of the condition and disease outcomes in patients with abdominal SS. MATERIALS AND METHODS: The study included 85 patients with the clinical picture of abdominal SS complicated by acute kidney injury. Group 1 (23 patients) received combined detoxification: SPF and continuous renal replacement therapy (CVVHDF). Group 2 (62 patients) received isolated CVVHDF. A comparative analysis of the main clinical and laboratory parameters and treatment outcomes was performed between the groups. RESULTS: The use of combined detoxification made it possible to reduce markers of systemic endogenous intoxication: C-reactive protein from 225.4 (211; 248.4) to 210.5 (180.39; 230.18) mg/l by the 3rd day of therapy (6.6 %; p = 0.0016), by the 5th–7th–10th days 156.17 (110.67; 180.62), 87 (74.5; 94.1), 62.2 (45.7; 71), respectively (30.7–61.4–72.4 %; p = 0.044; p = 0.0001; p = 0.0001); interleukin-6 demonstrated a decrease of 12.2 % by the 2nd day (p = 0.017) and 35.5, 39.4, 45.7 and 52.4 % by the 3rd–5th–7th–10th days of therapy, respectively (p = 0.022; p = 0.009; p = 0.0018; p = 0.0001); leukocytes from 19.7 (17.7; 22.4) to 17.25 × 109/l (14.65; 19.15) by the 3rd day (12.4 %; p = 0.00045), and 10.9 (9.3; 14.1) by the 10th day (44.7 %; p = 0.00048). Severity of organ dysfunction (SOFA) from 6 (4; 6) on the 1st day to 4 (3; 5) points by the 3rd day of therapy (p = 0.026). A significant difference in survival was obtained (p = 0.037). CONCLUSIONS: Combined detoxification consisting of SPF and CVVHDF allows for rapid normalization of laboratory markers of systemic inflammatory response syndrome and improves patient survival.
- Open Access
- 31 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (8) , 5957
Association of cell-free DNA with the length of ulcerated plaque in the infarct-related artery and the myocardial infarct size among patients with ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
Aim. To evaluate the changes of cell-free DNA (cfDNA) levels before and after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute coronary syndrome (STE-ACS). To identify associations of cfDNA concentration before and after PCI with complications and length of ulcerated plaque in patients with STE-ACS.Material and methods. This prospective single-center observational pilot study included 44 patients with STE-ACS admitted to the cardiac intensive care unit during the period of May-August 2023. In all patients, along with standard laboratory tests, cfDNA level was measured upon admission and 24 hours after PCI. Assessment of cfDNA associations before and after PCI was carried out in relation to following significant complications and conditions in STE-ACS patients: death, acute left ventricular failure (ALVF), acute heart failure (AHF), arrhythmia, number of stents implanted, number of segments with impaired local contractility, total stent length.Results. The mean age of the patients was 60,6±9,6 years, of which 74,6% were men. TIMI 0-1 flow was recorded in 93,2% of the subjects. The most common complications were cardiogenic shock (18,4%), arrhythmia (16,9%), AHF (13,6%), ALV (11,9%). Death was recorded in 8,5%. Implantation of 1 stent in PCI was performed in 75% of cases, while in the rest, 2 or more stents were implanted. The proportion of patients with impaired local contractility was 90%, the median stent length was 24,0 (20,0-50,0) mm. CfDNA level on admission did not differ from level after PCI 94,5 (78,3-155,5) ng/ml vs 115,0 (71,0-152,0), p=0,46. However, it significantly exceeded the cfDNA concentration from a group of healthy volunteers (78,0 (59,7-106,0), p=0,017). Characteristic curve showed significant relationships both for the concentration of cfDNA before (with implantation of 2 or more stents (AUC 0,71 with 95% confidence interval (CI) 0,56-0,86, p=0,039), stent length >24 mm (AUC 0,73 with 95% CI 0,58-0,89, p=0,009)) and after PCI (with the number of impaired local contractility segments (AUC 0,73 with 95% CI 0,57-0,89, p=0,014)). If the cfDNA level before PCI was >90 ng/ml, the risk of implantation of 2 or more stents per procedure increased by 5,4 times (odds ratio (OR) 5,4, 95% CI 1,11-28,93, p=0,044). The risk of a stent length >24 mm with pre-PCI cfDNA >107 ng/ml increased 9-fold (OR 9,0 with 95% CI 2,2-36,9, p=0,001), and the cfDNA level after PCI >105 ng/ml increased the risk of impaired local left ventricular (LV) contractility in 2 or more segments by 5 times (OR 5,0, 95% CI 1,23-20,3).Conclusion. In the studied group of patients with STE-ACS subject to intervention, the cfDNA concentration before PCI was associated with the implantation of ≥2 stents and the stent length (>24 mm). CfDNA level before PCI was associated with the number of segments of impaired local LV contractility (≥2).
- 31 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (8) , 5957
Open AccessAssociation of cell-free DNA with the length of ulcerated plaque in the infarct-related artery and the myocardial infarct size among patients with ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
Aim. To evaluate the changes of cell-free DNA (cfDNA) levels before and after percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute coronary syndrome (STE-ACS). To identify associations of cfDNA concentration before and after PCI with complications and length of ulcerated plaque in patients with STE-ACS.Material and methods. This prospective single-center observational pilot study included 44 patients with STE-ACS admitted to the cardiac intensive care unit during the period of May-August 2023. In all patients, along with standard laboratory tests, cfDNA level was measured upon admission and 24 hours after PCI. Assessment of cfDNA associations before and after PCI was carried out in relation to following significant complications and conditions in STE-ACS patients: death, acute left ventricular failure (ALVF), acute heart failure (AHF), arrhythmia, number of stents implanted, number of segments with impaired local contractility, total stent length.Results. The mean age of the patients was 60,6±9,6 years, of which 74,6% were men. TIMI 0-1 flow was recorded in 93,2% of the subjects. The most common complications were cardiogenic shock (18,4%), arrhythmia (16,9%), AHF (13,6%), ALV (11,9%). Death was recorded in 8,5%. Implantation of 1 stent in PCI was performed in 75% of cases, while in the rest, 2 or more stents were implanted. The proportion of patients with impaired local contractility was 90%, the median stent length was 24,0 (20,0-50,0) mm. CfDNA level on admission did not differ from level after PCI 94,5 (78,3-155,5) ng/ml vs 115,0 (71,0-152,0), p=0,46. However, it significantly exceeded the cfDNA concentration from a group of healthy volunteers (78,0 (59,7-106,0), p=0,017). Characteristic curve showed significant relationships both for the concentration of cfDNA before (with implantation of 2 or more stents (AUC 0,71 with 95% confidence interval (CI) 0,56-0,86, p=0,039), stent length >24 mm (AUC 0,73 with 95% CI 0,58-0,89, p=0,009)) and after PCI (with the number of impaired local contractility segments (AUC 0,73 with 95% CI 0,57-0,89, p=0,014)). If the cfDNA level before PCI was >90 ng/ml, the risk of implantation of 2 or more stents per procedure increased by 5,4 times (odds ratio (OR) 5,4, 95% CI 1,11-28,93, p=0,044). The risk of a stent length >24 mm with pre-PCI cfDNA >107 ng/ml increased 9-fold (OR 9,0 with 95% CI 2,2-36,9, p=0,001), and the cfDNA level after PCI >105 ng/ml increased the risk of impaired local left ventricular (LV) contractility in 2 or more segments by 5 times (OR 5,0, 95% CI 1,23-20,3).Conclusion. In the studied group of patients with STE-ACS subject to intervention, the cfDNA concentration before PCI was associated with the implantation of ≥2 stents and the stent length (>24 mm). CfDNA level before PCI was associated with the number of segments of impaired local LV contractility (≥2).
- Open Access
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 75-80
The first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 75-80
Open AccessThe first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.